- Crossmark names Janet Carter-Smith VP
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Facing pharmacy trends for the remainder of the year
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
PITTSBURGH A U.S. District Court has blocked Canadian generic drug maker Apotex from selling generic versions of an antidepressant drug.
Generic drug maker Mylan said Tuesday that it had obtained a temporary restraining order from the U.S. District Court for the District of New Jersey prohibiting Apotex from selling generic versions of the drug Paxil CR (paroxetine hydrochloride), an extended-release formulation of GlaxoSmithKline’s Paxil.
The order also prohibits GlaxoSmithKline from supplying Apotex with a generic version of the drug. The court has scheduled further hearings for Oct. 18.